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Background: Metoprolol, a selective beta-1 blocker, is available in two different salt forms in 
the market – metoprolol succinate (MS) and metoprolol tartarate (MT). Both the formulations are 
Food and Drug Administration approved for the treatment of hypertension. Several studies have 
shown similar efficacies between the two salts; however, they differ in their pharmacokinetic 
properties and are therefore priced differently. The primary objective of this study was to compare 
the overall health care expenditures of hypertensive patients on MT and MS to see if the price 
difference in the two preparations is offset by savings in overall expenditure.
Methods: Two cohorts of patients using MT and MS were selected from the 2008 Medical 
Expenditure Panel Survey. Propensity score matching technique was used to balance the cohorts 
on various parameters such as demographic information, insurance status, and comorbidity 
score. Patients using MT were matched to patients using MS on the logit of propensity score 
using calipers of width equal to 0.2 of the standard deviation of the logit of the propensity 
score. Multiple regression analysis was carried out to examine the association between health 
expenditure and type of metoprolol salt, adjusting for other covariates.
Results: A total of 742 patients were found to use metoprolol (MT-388, MS-354). After 
propensity score matching, a total of 582 patients were left in the sample for final analysis 
(291 patients in each cohort). The average annual health care expenditure was slightly higher in 
the MT cohort; however, after adjusting for covariates in a multivariate analysis, the difference 
was found to be statistically insignificant (P = 0.23).
Conclusion: Both the products of metoprolol were found to have similar average annual total 
health care expenditure; however, MS once a day has higher out-of-pocket cost.
Keywords: hypertension, cost, propensity score
Introduction
Hypertension is a condition associated with high morbidity and mortality.1 It is also a 
risk factor, albeit, a manageable one, for conditions like stroke, kidney failure, heart 
failure, and myocardial infarction.2,3 As of 2004, one out of every three individuals 
in the US was diagnosed with hypertension. This translates to 72 million Americans 
in 2004.4 By 2030, an additional 27 million individuals are expected to be diagnosed 
with hypertension.5
The comorbidities, high prevalence rates, and the chronic nature of hypertension 
generate substantial economic burden for both the patient and the US health care 
  system. The total hypertension-related costs are projected to rise from US$93.5 million 
in 2010 to US$240.1 million in 2030.5 Previous research has shown that systematic 
control of blood pressure can result in considerable cost savings.6,7 Additionally, 
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pharmacoeconomic analysis and comparative effectiveness 
research can help in determining cost-effective treatment 
choices leading to additional cost savings.
The treatment regimen for hypertension is burdensome 
for the patient in terms of cost and adherence considering 
the fact that it is a chronic condition that is usually treated 
with two or more medications.8 Research has shown that 
adherence to a treatment regimen can lead to better clinical 
outcomes.6,9,10 However, in the general population, adherence 
to all antihypertensive drug classes has been suboptimal, and 
the adherence to beta-blockers and diuretics has been the 
lowest amongst all antihypertensive drug classes.6,9
To increase adherence to the antihypertensive treatment 
regimen by reducing the pill burden, many medications are 
currently available in a once-daily dosage form. However, 
most of these drugs come at an additional daily cost. 
Once-daily medications reduce the pill burden and, as a result, 
may improve adherence by providing more convenience to 
the patient.6 As the clinical outcomes for both the preparations 
are similar because of the identical active ingredient, it would 
be interesting to find whether the improvement in adherence 
can offset the additional cost by producing savings in overall 
health care expenditure. In this study, the authors attempted to 
answer this question by analyzing the health care expenditures 
and the drug expenditures of the two products of metoprolol 
in the treatment of hypertension.
Metoprolol is a selective beta-1 blocker lacking intrinsic 
sympathomimetic activity. It is available in two different 
formulations, each a different salt – metoprolol tartarate 
(MT), which is taken twice a day, and metoprolol succinate 
(MS), an extended-release form, taken once a day in the 
treatment of hypertension. Both MT and MS are Food and 
Drug Administration (FDA) approved for the treatment of 
hypertension and angina pectoris; however, MS is also FDA 
approved for the reduction of mortality in patients with heart 
failure (New York Heart Association Class II or Class III).11 
Studies have shown similarity in outcomes between the two 
products in the treatment of hypertension.12,13 However, they 
are different in terms of their cost. MS has an average whole-
sale price (AWP) of US$52.45/30 pills (30-day supply), and 
MT has an AWP of US$34.09/60 pills (30-day supply).14 
Moreover, the acquisition price of both MT and MS could 
be much lower since both of these drugs are available as 
generic products.
The main objective of this study was to compare the 
impact of the metoprolol products on overall health care 
expenditure and prescription drug expenditure using 
  population-based data of matched cohorts. The authors 
examined whether a specific type of metoprolol product was 
associated with changes in total health care expenditures and 
prescription drug expenditure.
Methods
Data from the 2008 Medical Expenditure Panel Survey 
(MEPS) was used to perform a retrospective cross-sectional 
analysis. MEPS is a nationally representative database main-
tained by the Agency for Healthcare Research and Quality 
under the purview of the United States Department of Health 
and Human Services. It is a database of the results of the 
large-scale surveys of families and/or individuals, health 
care providers, employers, and payers.
The medical conditions file HC-120 and the prescribed 
medicines file HC-118 were used to identify patients being 
treated for hypertension (International Classification of 
Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] 
codes 401–405) using MT or MS. Patients using MT or MS 
were filtered using the medication name: metoprolol, meto-
prolol tart*, and metoprolol succ*. The fields that did not have 
a medication name were then identified using the eleven-digit 
National Drug Code (NDC) in an effort to not leave out any 
of the hypertensive patients on MT or MS.
MT and MS are approved for the treatment of hyperten-
sion and angina. Since this study was limited to the utility 
of MT and MS in the treatment of hypertension, patients 
on MT or MS who had a record of angina (identified by 
ICD-9 code 413) in addition to a record of hypertension were 
excluded from the study.
The patient cohorts obtained were then merged with 
the full-year consolidated data files (HC-121) to get demo-
graphic information, as well as the expenditure information 
of the patients.
Statistical analysis
After the patients meeting all requirements described in the 
inclusion/exclusion criteria (Figure 1) were selected, they 
were divided into two separate groups depending upon the 
type of metoprolol product (MT or MS). Baseline charac-
teristics were compared between the patient cohorts, and 
descriptive statistics were calculated. To achieve the balance 
in baseline characteristics and to account for the selection 
bias, propensity score matching was applied. Propensity score 
matching is a technique that aims at adjusting for selection 
bias in nonexperimental, nonrandomized, and retrospective 
observational studies like the present one. Propensity score 
matching allowed mirroring each patient in the MS cohort 
with a patient with similar predefined characteristics in the 
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MT cohort. The following characteristics were used to match 
patients in both cohorts: age, sex, race, ethnicity, income, 
Charlson comorbidity index (CCI), and insurance type. Based 
on the balancing guidelines,15 the one-to-one caliper match-
ing technique produced the best balance. As a result, patients 
were matched using the calipers of width equal to 0.2 of the 
standard deviation of the logit of the propensity score.
To analyze the association between type of metoprolol 
salt and health care expenditure, a multiple regression 
analysis using a generalized linear model with a log link 
function and gamma distribution was used, adjusting for 
age, sex, race, ethnicity, income, CCI, and insurance type. 
Total health care expenditure, as defined in MEPS, was the 
sum of direct payments for care provided during the year, 
including out-of-pocket payments and payments by private 
insurance, Medicaid, Medicare, and other sources. The total 
prescription drug expenditure was the sum of all prescription 
drugs payments irrespective of the source of payment for the 
drugs. Interpretation was carried out by taking the natural 
exponential [exp(β1)] of the regression coefficient for the 
expenditure variables. The level of statistical significance 
was P # 0.05, and all statistical computations were done with 
SAS software (v 9.1; SAS Institute Inc, Cary, NC).
Results
Of the 33,066 unweighted observations, 6658 were identified 
to use metoprolol. Among these users, 798 were found to be 
diagnosed for hypertension. After excluding patients who 
are also diagnosed with angina, the number of patients was 
reduced to 742. Based on the type of metoprolol they used, 
388 patients were found to be using MT and 354 were using 
MS. After propensity score matching, the two cohorts were 
further reduced to 291 each to carry out the final analysis. 
Baseline characteristics (listed in Table 1) were similar in both 
the cohorts as a result of the propensity score matching.
The average health care expenditure was found to be 
similar between the two cohorts. The MT cohort had slightly 
higher average total health care expenditure (US$10,779). 
The average prescription drug expenditure was slightly lower 
in the MT cohort (US$2675) compared with MS (US$2761) 
 ( Figure 2). The results of the regression analysis showed 
that the total health care expenditure was not significantly 
associated with the type of metoprolol product being utilized 
(Table 2). Upon converting the coefficient into its natural 
exponential form, the total health care expenditures of MT 
users was found to be 1.01 (P = 0.23) times higher, than 
the corresponding expenditures of the MS users; however, 
Total number of survey participants in
MEPS 2008 = 33,066 records
Total number of patients on either MT or
MS = 6,658
Total number of patients on MT or MS
with diagnosis of hypertension = 798
After excluding 56 angina patients, total 
number of patients remaining = 742
MS cohort (unmatched); n = 354 MT cohort (unmatched); n = 388
MT cohort (matched); n = 291 MS cohort (matched); n = 291
Figure 1 Patient selection criteria of MT and MS cohorts.
Abbreviations: MEPS, Medical Expenditure Panel Survey; MS, metoprolol succinate; MT, metoprolol tartarate.
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the P value indicated that this association is not statistically 
significant. In case of prescription drug expenditure, MS 
users were found to be 1.06 or 6% (P = 0.019) times higher, 
respectively, than the corresponding expenditures of the 
MS users.
Among the variables used to adjust for overall health care 
expenditure employment (P $ 0.001) status was found to be 
significantly associated. None of the other variables were 
significantly associated with the overall health expenditure. 
In case of prescription drug expenditure, however, along 
Table 1 Demographic characteristics of the MT and MS cohorts
MT (n = 291) MS (n = 291) P-value
gender, n (%)
  Male 138 (47.42) 138 (47.42) 1.0000
  Female 153 (52.58) 153 (52.58) 1.0000
Age group, n (%)
  0–40 years 12 (4.12) 15 (5.15) 0.5544
  41–65 years 140 (48.11) 147 (50.51) 0.5617
  .65 years 139 (47.77) 129 (44.34) 0.4056
income, n (%, USD)
  ,20,000 86 (29.55) 78 (26.80) 0.4610
  20,000–49,999 92 (31.61) 97 (33.33) 0.6581
  50,000–100,000 80 (27.49) 80 (27.49) 1.0000
  .100,000 33 (11.35) 36 (12.38) 0.7005
Race, n (%)
  White 209 (71.82) 207 (71.13) 0.8543
  African-American 65 (22.33) 61 (20.96) 0.6873
  Other minorities 17 (5.85) 23 (7.91) 0.3256
Ethnicity, n (%)
  Hispanics 40 (13.74) 43 (14.77) 0.7221
  non-Hispanics 251 (86.26) 248 (85.23) 0.7221
insurance status, n (%)
  Public insurance 107 (36.77) 112 (38.48) 0.6688
  Other insurance 168 (57.73) 161 (55.32) 0.5583
  Uninsured 16 (5.50) 18 (6.20) 0.7237
Employment status, n (%)
  Employed 88 (30.24) 96 (32.99) 0.4757
  Unemployed 203 (69.76) 195 (67.01) 0.4757
Charlson’s comorbidity index 2.2 2.3 0.734
Abbreviations: MS, metoprolol succinate; MT, metoprolol tartarate.
MT
$9,810
$2,675
Total health expenditure Total Rx expenditure AWP
$34.09
$52.45
$2,761
$10,779
MS
Figure 2 Health expenditure comparison and cost comparison of MT and MS.
Abbreviations: AWP, average wholesale price; MS, metoprolol succinate; MT, metoprolol tartarate; Rx, prescription.
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with   employment status (P $ 0.001), age categories 40–65 
(P = 0.0214), and .65 (P = 0.0113) were also significantly 
associated.
Discussion
Previous research on comparing different formulations of 
the same drug molecule has been mostly limited on estab-
lishing efficacy or effectiveness of products. In the case of 
metoprolol, existing literature documents clinical outcomes 
associated with MT and MS,12,13 but no research is available 
on how these two products compare with each other in terms 
of total health care costs incurred. The results of the current 
study show that the overall expenditures of hypertensive 
patients on twice-daily MT are not significantly different than 
the overall expenditures of once-daily MS. However, since 
the cost of a once a daily formulation is almost two times a 
twice-daily formulation, MS is associated with significantly 
higher out-of-pocket cost. The similarities in overall health 
care expenditure indicate that both the products are equally 
beneficial, and once daily MS may not offer any additional 
advantage to justify the additional drug cost.
Adherence is a major issue in the treatment of hyperten-
sion, especially if approximately 50% of the hypertensive 
population discontinues their antihypertensive medication 
within the first 6–12 months of initiation of therapy.16 MS 
being a once-daily formulation has a clear advantage over 
MT in terms of improving adherence by providing more ease 
to the patient. Previous studies have shown that simplifica-
tion of dosing regimens using once-daily medications and/or 
combination medications does help in improving adherence 
to the regimen.6,17–22 Most of these studies show that there 
is no significant reduction in the blood pressure associated 
with increase in adherence to the treatment regimen with 
a once-daily regimen when compared with a twice-daily 
regimen in the treatment of hypertension.18–20,22 On the other 
hand, there are studies that show that once-daily   medications 
Table 2 Factors affecting differences in total healthcare and total Rx expenditures
Variable Total health care expenditure Total Rx expenditure
Estimate P-value Estimate P-value
intercept 2.1153 ,0.0001 1.8548 ,0.0001
Cohort
  MT Reference – Reference –
  MS 0.0148 0.2319 0.0366 0.0208
Comorbidity index -0.0006 0.7971 -0.0002 0.9526
gender
  Female Reference – Reference –
  Male -0.0052 0.6904 0.0101 0.5480
Age (years)
  0–40 Reference – Reference –
  41–65 0.0232 0.4461 0.0895 0.0214
  .65 0.0499 0.1201 0.1036 0.0113
income (USD)
  ,20,000 Reference – Reference –
  20,000–49,999 -0.0269 0.1033 -0.0183 0.3865
  50,000–100,000 -0.0016 0.9321 0.0043 0.8574
 . 100,000 -0.0064 0.7930 -0.0380 0.2261
Race
  White Reference – Reference –
  African-American 0.0011 0.9482 -0.0178 0.3939
  Other minorities -0.0318 0.2064 -0.0020 0.9505
Ethnicity
  non-Hispanic Reference – Reference –
  Hispanic -0.0141 0.4619 -0.0112 0.6484
insurance status
  Uninsured Reference – Reference –
  Public insurance 0.0185 0.5331 0.0667 0.0776
  Private insurance 0.0253 0.3811 0.0537 0.1462
Employment status
  Unemployed Reference – Reference –
  Employed -0.0940 ,0.0001 -0.0886 ,0.0001
Abbreviations: MS, metoprolol succinate; MT, metoprolol tartarate; Rx, prescription.
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not only improve adherence, but also decrease blood pres-
sure, and are cost-effective as well.21,23 As a result, there 
is lack of established relationship between adherence and 
lowering of blood pressure.17,24 Hence, in this study, the 
similarity in overall expenditure questions the advantage of 
MS having a once-daily dosing regimen, as the total health 
care expenditure is a good predictor of the overall health 
status of a hypertensive individual. Currently, very little is 
known about the extent of difference in adherence required 
to produce any noticeable effect in terms of overall health 
status and health care expenditure. Further research is war-
ranted to examine adherence rates in similar cohorts and 
its impact on overall health status. Although both MS and 
MT have a similar impact on total health care expenditure, 
one key difference to be noted is, only MS is indicated for 
the treatment of heart failure by the FDA.10 Heart failure is 
shown to be associated with hypertension.25 Therefore, in 
heart failure patients who are hypertensive, MS is an obvi-
ous choice given its FDA-approved indication for heart 
failure. Moreover, the pharmacokinetic profile of MT is 
associated with higher utilization of health care services and 
inferior outcomes when compared with MS in heart failure 
patients.26 In addition to the inferiority of MT, heart failure 
is associated with a higher risk of hospitalization, which 
can lead to increased costs; prevention of hospitalization 
with the use of MS can save money in the long run in this 
patient population.27
MT is available as a discounted generic in many 
  pharmacies. The discounts available on MT have increased 
access to this medication, even with hypertensive patients 
who are uninsured.28 This access to medications at a deeply 
discounted price with the same efficacy will ensure that 
the hypertensive patients do not go without medications 
due to lack of insurance. The rising cost of prescription 
drugs presents a significant challenge to individual con-
sumers. Finding affordable treatment options has become 
a very important need to reduce financial burden on both 
patients and   payers. Future research should be carried out 
to produce more evidence towards economic comparison 
of different dosage forms of widely prescribed drugs 
such as metoprolol using diverse patient populations to 
generate potential cost savings without compromising 
health outcomes.
Some clinicians initiate therapy of MT as a once daily 
dose; however, with the MEPS database, it becomes difficult 
to identify these patients. The outcomes of this therapy are 
yet to be ascertained. Nonetheless, if the outcomes of this 
therapeutic regimen are similar to that of MT given twice a 
day and/or MS given once a day, there could be consider-
able reduction in the costs associated with the treatment of 
  hypertension using MT. Further clinical and pharmacoeco-
nomic research of this therapeutic regimen could present 
clinicians with other cost savings.
Given the sample size and the complexity of the 
characteristics and the disease of hypertension, the 
socioeconomic characteristics and their association with 
health care expenditure needs to be carefully interpreted 
from this study. Previous research has shown that females 
have higher overall expenditures, but males are associated 
with more spending on drugs, physician service, and 
hospital service.29,30 Although the results of this study 
do not show such association, it demonstrates that the 
expenditure to age correlation is supported by existing 
literature.29,30 In addition, previous studies have shown 
conflicting results for the association between expenditure 
and employment status and, hence, the results of our 
study should be carefully interpreted.29,30 In short, with 
the limitations of this study, which are listed below, 
such associations may not be fully confirmed based on a   
single study.
Limitations
MEPS, being a self-reported survey, is subject to common 
limitations such as recall bias and missing information associ-
ated with all survey-based retrospective datasets. However, 
the pharmacy records are verified for accuracy and complete-
ness of the data, which includes the NDC of the drug, the 
date the prescription is filled and/or refilled, the quantity 
dispensed, the amount paid by the patient, the amount paid 
by any third-party payers, and the type of third-party payer 
during any calendar year.
Another limitation was lack of information on the sever-
ity of disease. Although the results were adjusted for the 
comorbidity index, availability of clinical measures such as 
the blood pressure of the patients, side effects of the medica-
tions, or discontinuation of the medication would have been 
helpful to assess the safety and efficacy of the regimen in 
each of the cohorts.
Also, with hypertension being a “silent” disease, many 
hypertensive patients will not be diagnosed with hyperten-
sion, and there would be an underestimation of the problem 
of hypertension. In addition, with the ICD-9 codes limited 
to just three digits, we lose the specificity that we could 
otherwise have with a five-digit ICD-9 code.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
54
Vaidya and PatelClinicoEconomics and Outcomes Research 2012:4
Moreover, the management of hypertension is a complex 
process, considering the comorbidities associated with it. 
With the MEPS database, it would be difficult to account for 
all the dimensions of the pharmacotherapy of hypertension. 
The use of CCI and propensity score matching would help in 
balancing the comorbidities in each cohort and hence reduce 
the chance of bias.
Conclusion
With the increasing health care costs associated with the 
treatment of hypertension, it is imperative to analyze the treat-
ment options to avoid unnecessary costs for the health care 
system. The results of this study contribute towards decision 
making involved in formulary management and by   clinicians 
treating patients with hypertension. Further analysis such 
as the   present one could help to determine cost-saving options 
across all classes and combination antihypertensive agents 
that are available in the market.
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